The Micromedex Drugdex has been a CMS designated drug compendium for non-FDA approved oncologic use of FDA-approved drugs since 2008. The rigorous scientific literature review employs experienced pharmacists, and literature analysts for the initial review and external oncologists for consensus of reviewed content, with use of Delphi methodology. Since 2016, 1 in 10 indications required invocation of Delphi methodology and there are currently ~160 non-FDA oncologic uses for FDA approved drugs in the Drugdex compendium.
Describe the new knowledge and additional skills the participant will gain after attending your presentation.:
The audience will understand the rigorous methodology used by the Micromedex editorial and content curation team in evaluating literature on non-FDA approved oncologic uses of FDA approved drugs and application of the Delphi consensus methodology in an evidence-based literature review process.
Elisabeth Scheufele (Presenter)
IBM Watson Health
Mya Baca, IBM Watson Health
Stacy Laclaire, IBM Watson Health
Henry Feldman, IBM Watson Health
Nawshin Kutub, IBM Watson Health
Brett South, IBM Watson Health
Gretchen Jackson, IBM Watson Health